Lin Chung

Lin Chung is a seasoned professional in global patient safety and regulatory documentation, currently serving as Associate Director of Global Patient Safety - Safety Science at Eli Lilly and Company since September 2025. Prior experience includes a Director role at Bristol Myers Squibb where leadership was provided for global processes concerning Investigator’s Brochures and health authority responses, along with guiding a team in the development of various aggregate safety reports. Lin Chung's background also encompasses significant roles at Celgene and Johnson & Johnson, focusing on aggregate safety reporting and pharmacovigilance, with a strong emphasis on regulatory compliance and quality assurance. Lin Chung holds a Doctorate in Pharmacy from the University of the Sciences in Philadelphia, earned in 2009.